FDA Approves Dexmethylphenidate ER Capsules for the Treatment of ADHD
May 27, 2005, 18:14, Reviewed by: Dr.
|
|
"Focalin XR provides a new treatment option for adults, adolescents and children to address the many difficult symptoms of ADHD."
|
By Novartis Pharmaceuticals ,
Novartis Pharmaceuticals Corporation today announced that the U.S. Food and Drug Administration (FDA) has approved Focalin XR(TM) (dexmethylphenidate HCl) extended-release capsules for the treatment of Attention-deficit/ Hyperactivity Disorder (ADHD) in adults, adolescents and children.
"Focalin XR provides a new treatment option for adults, adolescents and children to address the many difficult symptoms of ADHD," said Thomas Spencer, M.D., Associate Professor of Psychiatry, Harvard Medical School and Assistant Director of the Pediatric Psychopharmacology Research Program at Massachusetts General Hospital."Focalin XR provides patients with a treatment that starts working quickly to alleviate symptoms with the advantage of a once-daily dose."
In adults and children, the core symptoms of ADHD are inattention, impulsivity and hyperactivity; however, in adults symptoms of hyperactivity often subside with maturity or may manifest differently. ADHD is one of the
most common psychiatric disorders of childhood and is estimated to affect five to seven percent of children. Many children with ADHD will continue to experience symptoms into adulthood. ADHD is estimated to affect approximately four percent of the adult population.
"We are pleased to introduce Focalin XR as a valuable treatment to help adults, adolescents and children effectively manage their symptoms of ADHD," said Paulo Costa, head of Pharma Americas and CEO, Novartis Pharmaceuticals Corporation. "Novartis has been a leader in helping ADHD patients since we first introduced Ritalin(R) in the 1960s. The addition of Focalin XR further emphasizes this commitment as it provides a new treatment option to address the many difficult symptoms of ADHD."
Focalin XR was generally well tolerated. There were no significant changes in patient weight or vital signs, such as sitting pulse or sitting blood pressure, in adults or children.
The most common side effects in adults and children include decreased appetite, headache, dyspepsia, anxiety,
insomnia, feeling jittery and anorexia.
The approval of Focalin XR for the treatment of ADHD was based on efficacy and safety data from clinical trials involving approximately 320 adults, adolescents and children diagnosed with ADHD.
Adult Study
A 5-week, double-blind, placebo-controlled study involving 221 men and women with ADHD aged 18 to 60, demonstrated Focalin XR to be safe and effective in treating ADHD symptoms in adults. Patients received Focalin XR or placebo once daily. Results indicated that Focalin XR was statistically superior to placebo, based on changes in the Diagnostic and Statistical Manual-IV (DSM-IV) ADHD Rating Scale, a standard assessment tool used in ADHD.
Secondary measures included evaluations rated by patients, clinicians and observers.
Following the completion of the 5-week double-blind clinical trial, 170 patients continued into a 6-month open-label extension phase. Patients who switched from placebo to Focalin XR showed significant clinical improvement and patients continuing treatment with Focalin XR continued to show increasing benefits over six months, based on changes in the DSM-IV ADHD Rating Scale.
Focalin XR was generally well tolerated. The most frequently reported adverse events included headache, insomnia and decreased appetite.
Pediatric Studies
The efficacy and tolerability of Focalin XR for the treatment of ADHD in children was demonstrated in a pivotal clinical trial of children and adolescents aged 6 to 17 years diagnosed with ADHD.
In this trial, 103 ADHD patients aged 6 to 17 years received Focalin XR or placebo once daily for seven weeks. Results indicated that Focalin XR was statistically superior to placebo, based on the Conners' ADHD/DSM-IV Scales for Teachers (CADS-T). The CADS-T Rating Scale is a tool used in clinical trials to assess attention and behavior.
In an additional trial of 54 pediatric patients aged 6 to 12 years, investigators evaluated the efficacy of Focalin XR 20 mg/day at various points throughout the day. Focalin XR was found to be significantly more effective than placebo in treating ADHD symptoms after just one hour, as measured by the Swanson, Kotkin, Agler, M-Flynn, and Pelham (SKAMP) Rating Scale. The SKAMP Rating Scale evaluates attention and behavior in clinical trials.
In these studies, Focalin XR was generally well tolerated. The most frequently reported adverse events included decreased appetite, headache, dyspepsia, upset stomach and anxiety.
About Focalin XR
Focalin XR is an extended-release form of Focalin(TM) (dexmethylphenidate HCl). Focalin is an advance in single-isomer technology and is formulated by isolating the active d-isomer of methylphenidate. Data suggest that the d-isomer is responsible for the effective management of the symptoms of ADHD.
Focalin XR is available in 5, 10 and 20 mg capsules for oral administration.
Like most drugs approved for the treatment of ADHD, Focalin XR is contraindicated in patients known to be hypersensitive to the drug or to methylphenidate, in patients with glaucoma, and in patients with motor tics or
with a family history or diagnosis of Tourette's syndrome. It is also contraindicated during treatment with monoamine oxidase inhibitors and also within a minimum of 14 days following discontinuation of a monoamine oxidase inhibitor (hypertensive crises may result).
In addition, like most drugs approved for the treatment of ADHD, Focalin XR is a schedule II drug and should be given cautiously to patients with a history of drug dependence or
alcoholism.
About ADHD
ADHD is a neurobiologic disorder that interferes with an individual's ability to regulate activity level and behavior, and sustain focus in developmentally appropriate ways. In adults, it is associated with poor functioning in educational and occupational environments, as well as
emotional, social and economic problems. For further information, visit http://www.ADHDInfo.com. 
- U.S. Food and Drug Administration (FDA)
www.novartis.com
For further information about Focalin XR, visit http://www.FocalinXR.com.
About Novartis ADHD Treatments
The Novartis ADHD product portfolio includes Ritalin (methylphenidate HCl) tablets, Ritalin-SR(R) methylphenidate HCl) sustained-release tablets, Ritalin LA(R) (methylphenidate HCl) extended-release capsules, Focalin
(dexmethylphenidate) tablets, and Focalin XR extended-release capsules. These products are classified as schedule II drugs.
Celgene Corporation (Nasdaq: CELG) of Summit, New Jersey granted Novartis Pharma AG an exclusive worldwide (excluding Canada) license covering its intellectual property rights associated with Ritalin LA, Focalin and Focalin XR. Pursuant to an agreement between Novartis Pharma AG and Novartis Pharmaceuticals Corporation, Novartis Pharmaceuticals Corporation markets Focalin in the U.S.
Ritalin LA and Focalin XR were developed with SODAS(R) technology (spheroidal oral drug absorption system), a multiparticulate drug delivery system of Elan Corporation, plc (NYSE: ELN). Focalin XR is being supplied to Novartis under an exclusive worldwide (except Canada) royalty and
manufacturing agreement between Elan Corporation, plc, and Novartis Pharma AG.
Novartis Pharmaceuticals Corporation has commercialization rights to Ritalin LA and Focalin XR in the U.S.
The foregoing press release contains forward-looking statements that can be identified by forward-looking terminology such as, "to address," "introduce" or similar expressions, or by express or implied statements regarding potential future approvals of, or potential future revenues from Focalin XR. Such statements involve known and unknown risks, uncertainties and other factors that may cause the actual results to be materially different from any future results, performance, or achievements expressed or implied by such statements. There can be no guarantee that Focalin XR will reach any particular sales levels. In particular, management's expectation regarding the commercial success of Focalin XR could be affected by among other things,
uncertainties relating to product development, regulatory actions or delays or government regulation generally, the ability to obtain or maintain patent or other proprietary intellectual property protection and competition in general,
as well as factors discussed in the Form 20F filed with the Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results
may vary materially from those described herein anticipated, believed, estimated or expected. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any
forward-looking statements contained in this press release as a result of new information, future events or otherwise.
About Novartis
Novartis Pharmaceuticals Corporation researches, develops, manufacturers and markets leading innovative prescription drugs used to treat a number of diseases and conditions, including central nervous system disorders, organ transplantation, cardiovascular diseases, dermatological diseases, respiratorydisorders, cancer and arthritis. The company's mission is to improve people's lives by pioneering novel healthcare solutions.
Novartis has been a leader in the neuroscience area for more than 50 years, having pioneered early breakthrough treatments for Alzheimer's disease,Parkinson's disease, Attention-Deficit/Hyperactivity Disorder, epilepsy,
schizophrenia and migraine, many of which continue to be regarded as "gold standards" to this day. Novartis Neuroscience continues to be at the forefront of research and development of new compounds, is committed to addressing unmet medical needs and to supporting patients and families affected by these disorders.
Located in East Hanover, New Jersey, Novartis Pharmaceuticals Corporation is an affiliate of Novartis AG (NYSE: NVS) -- a world leader in pharmaceuticals and consumer health. In 2004, the Group's businesses achieved
sales of USD 28.2 billion and pro forma net income of USD 5.6 billion. The Group invested approximately USD 4.2 billion in R&D. Headquartered in Basel, Switzerland, Novartis Group companies employ approximately 81,400 people and operate in over 140 countries around the world. For further information please consult http://www.novartis.com.
Contacts
Laurie Ostroff-Landau
Novartis Pharmaceuticals Corporation
+1 862 778 0319 (direct)
+1 973 493 7971 (mobile)
[email protected]
Gina Moran
Novartis Pharmaceuticals Corporation
+1 862 778 5567 (direct)
+1 973 476 3643 (mobile)
[email protected]
Julie Bane
Feinstein Kean Healthcare
+1 617 761 6762 (direct)
+1 617 821 1089 (mobile)
[email protected]
|
For any corrections of factual information, to contact the editors or to send
any medical news or health news press releases, use
feedback form
Top of Page
|
